Recently, KIRGEN Bio and Baigaole Bio signed a strategic cooperation agreement in Shanghai. The two sides will give full play to their respective resource advantages and jointly complete the research and development and industrialization of a number of life science solutions around the whole industrial chain of high-end cell culture and cell therapy.

Zhu Yiming, founder and chairman of KIRGRN Bio, Zhou Libo, co-president, Gu Guzhong, founder and chairman of Baigaole Bio, and Su Sizhou, senior investment manager of Sinopharm Zhongjin attended and witnessed the signing. Li Xinghuo, president of KIRGEN Bio, and Huang Yanhong, general manager of Baigaole Bio, signed the contract on behalf of both parties.

At present, life science equipment and consumables related to cell culture and cell therapy are still monopolized by imported manufacturers, and technological breakthroughs need to be completed in many fields, such as bottom technology, bottom new materials, core production technology and equipment control engineering technology. After years of research and development, KIRGEN Bio has provided high-quality high-end laboratory consumables for the downstream by achieving technological breakthroughs in the field of new materials and technologies at the bottom of life sciences, and on this basis, it has continuously expanded new products of cell culture consumables that can be independently controlled by the upstream. As a leading bioreactor enterprise, Bagol Bio has been developing products for a long time around the demand of biotechnology sector under Sinopharm Group. It is one of the few enterprises whose disposable bioreactor products related to small-scale, pilot-scale, scale-up and industrial production have been verified by domestic leading enterprises for a long time, and will vigorously develop the product expansion of domestic cell culture consumables in the future. The two sides will focus on their respective R&D advantages, realize technological complementarity, and jointly promote the research and development of a number of innovative products, including biological bags, cell reaction bags and cell factories.

After reaching the strategic cooperation, the two sides will make full use of their respective advantages, realize product complementation and channel sharing, and conduct all-round and in-depth cooperation in research and development, technology, production, quality and marketing, so as to achieve a win-win situation and jointly promote the innovative development of life sciences in China.